Already have an ACS ID? Log in
Renew your membership, and continue to enjoy these benefits.
Already an ACS Member? Log in here
Choose the membership that is right for you. Discount will be applied automatically at checkout.
Enjoy these benefits no matter which membership you pick.
Most Popular in Business
Roche and InterMune will develop and commercialize products from InterMune's hepatitis C virus protease inhibitor program. The agreement includes the firm's lead compound, ITMN-191, expected to enter clinical trials by year's end. The companies will also collaborate on second-generation protease inhibitors. InterMune will receive an up-front payment of $60 million and has the potential to reap up to $470 million in milestone payments. Roche will fund 67% of development costs; the companies will co-commercialize the product in the U.S. and share profits on a 50-50 basis.
This article has been sent to the following recipient: